Veeva Systems Inc. is headquartered in Pleasanton, California. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.33% per year.
For the second quarter of fiscal 2021, Veeva Systems expects revenues between $339 … Veeva Systems Q2 2021 ... Total revenue was $354 million, up 33% year-over-year. Total Revenues of $337.1M, up 38% Year-over-year; Subscription Services Revenues of $270.2M, up 36% Year-over-year ... March 26, 2020. A recent pick, Maxar, skyrocketed For 32 years, our Strong Buy list has averaged returns more than twice the market. Total Revenues of $353.7M, up 33% Year-over-year; Subscription Services Revenues of $283.5M, up 30% Year-over-year Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal second quarter ended July 31, 2020.
We use cookies to understand how you use our site and to improve your experience. PLEASANTON, CA — Aug 6, 2020 — Veeva Systems (NYSE: VEEV) will announce financial results for its second quarter ... May 28, 2020. Veeva is a leading global provider of industry-specific, cloud-based software solutions for the life sciences industry. The Zacks Consensus Estimate for the same stands at $2.55.Adjusted operating income is expected between $540 million and $545 million.Veeva Systems ended the second quarter of fiscal 2021 on a strong note. Subscription services revenues for the first quarter were $270.2 million, up from $198.1 million one year ago, an increase Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Revenues of $6.92 billion outpaced the consensus mark by 0.1%.PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. The Zacks Consensus Estimate for the metric is pegged at 63 cents.Adjusted operating income is estimated between $138 million and $140 million.For fiscal 2021, revenues are expected within $1.41-$1.42 billion, compared with the previously-issued range of $1.38-$1.39 billion. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic.If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page.
ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.The company’s revenues totaled $353.7 million, outpacing the Zacks Consensus Estimate by 4.1%.
“Thanks to the Veeva team for all the incredible innovation and execution that’s enabling our customers’ rapid move to digital so they can continue their critical work helping healthcare professionals and patients.” Fiscal 2021 First Quarter Results: Revenues : Total revenues for the first quarter were $337.1 million, up from $244.8 million one year ago, an increase of 38% year-over-year.
BofA Confident In Veeva Systems' Revenue Growth: Veeva's key second-quarter metrics such as revenues, in both subscriptions and services, and … In fact, Veeva Vault’s customer count has increased manifold in recent times.
In the same quarter last year, Veeva Systems … Q4 Subscription Services Revenues of $150.9M, up 26% Year-over-year PLEASANTON, CA — February 27, 2018 — Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal fourth quarter and full year ended January 31, 2018.
Long-term shareholders are already enjoying 12-month gains prior to the announcement.Don't be surprised to see the stock move on comments made during its conference call.
Volatility in the foreign currency exchange rate is an added woe.Veeva Systems currently carries a Zacks Rank #3 (Hold).A few better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. (Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. The management raised full-year guidance to reflect a stronger second half and a …